• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $RDNT alert in real time by email

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncology Holdings, Inc., which at the time was one of the nation's leading radiation and medical oncology companies.

    "We are very pleased to have a seasoned public company CFO like Mark join our board," said Anne McGeorge, Chairman of the Board of The Oncology Institute. "Mark brings tremendous experience in capital markets, fundraising strategies, strategic financial planning and payor strategy that will be invaluable to TOI in our next phase of growth."

    "I am very excited to join The Oncology Institute's Board of Directors," commented Mr. Stolper. "The Company's mission to provide leading-edge, cost-effective cancer care to improve outcomes and streamline the patient journey is critically important at this time in healthcare. I truly believe that TOI is poised for continued growth and profitability in the coming years."

    About The Oncology Institute

    Founded in 2007, The Oncology Institute (NASDAQ:TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

    Contacts

    Media

    The Oncology Institute, Inc.

    marketing@theoncologyinstitute.com

    Investors

    ICR Healthcare

    TOI@icrhealthcare.com



    Primary Logo

    Get the next $RDNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT
    $TOI

    CompanyDatePrice TargetRatingAnalyst
    RadNet Inc.
    $RDNT
    1/9/2026$92.00Overweight
    KeyBanc Capital Markets
    The Oncology Institute Inc.
    $TOI
    11/25/2025$5.00Buy
    Needham
    The Oncology Institute Inc.
    $TOI
    7/23/2025$8.00Outperform
    Noble Capital Markets
    The Oncology Institute Inc.
    $TOI
    7/16/2025$6.00Buy
    B. Riley Securities
    RadNet Inc.
    $RDNT
    6/13/2025$69.00Buy
    B. Riley Securities
    The Oncology Institute Inc.
    $TOI
    5/15/2025$7.00Buy
    BTIG Research
    RadNet Inc.
    $RDNT
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    RadNet Inc.
    $RDNT
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $RDNT
    $TOI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities

    LOS ANGELES, June 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it seeks to secure an incremental term loan in the aggregate principal amount of $200 million (the "Proposed 2026 Incremental Term Loan") pursuant to a proposed amendment (the "Proposed Amendment") to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the "Existing Credit Agreement" and, the transaction, the "Loan Transaction"). If

    6/3/26 8:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet to Host Men's Health Webinar on June 13, 2026

    LOS ANGELES, May 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of over 440 outpatient imaging centers and a premier developer of radiology digital health solutions, today announced it will host a free webinar for patients and the general public on Saturday, June 13, 2026, in recognition of National Men's Health Month. The event will feature presentations by radiologists on three of the most significant health conditions affecting American men today: coronary artery disease, prostate cancer and lung cancer. The clinical case for increased attention to

    5/28/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conference

    CERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D. Podnos, MD, MPH, FACS, Chief Medical Officer, will participate in a panel discussion at the APG Spring Conference on May 28, 2026, in San Diego. The session, "Engaging More Specialists in Value-Based Care," will bring together healthcare leaders to discuss the growing role of specialists in advancing value-based care. "Specialists play a critical role in delivering high-quality, coordinated care while helping improve outcomes and reduce the total cost of care," said Dr. Podnos. "As oncology c

    5/26/26 9:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $RDNT
    $TOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on RadNet with a new price target

    KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00

    1/9/26 9:07:04 AM ET
    $RDNT
    Medical Specialities
    Health Care

    Needham initiated coverage on The Oncology Institute with a new price target

    Needham initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $5.00

    11/25/25 8:00:05 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Noble Capital Markets initiated coverage on The Oncology Institute with a new price target

    Noble Capital Markets initiated coverage of The Oncology Institute with a rating of Outperform and set a new price target of $8.00

    7/23/25 9:21:53 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $RDNT
    $TOI
    SEC Filings

    View All

    RadNet Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - RadNet, Inc. (0000790526) (Filer)

    6/3/26 9:08:18 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    6/3/26 8:07:02 AM ET
    $RDNT
    Medical Specialities
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    5/22/26 4:30:17 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $RDNT
    $TOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Swartz David L was granted 2,946 shares, increasing direct ownership by 2% to 179,712 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/3/26 9:11:48 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Director Spurlock Gregory E. was granted 2,946 shares, increasing direct ownership by 56% to 8,236 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/3/26 9:11:34 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Director Jacobs Laura Pastre was granted 2,946 shares, increasing direct ownership by 11% to 29,953 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/3/26 9:11:21 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    $TOI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $156,595 worth of shares (38,500 units at $4.07), increasing direct ownership by 0.37% to 10,567,858 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    5/21/26 9:35:48 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $122,700 worth of shares (30,000 units at $4.09), increasing direct ownership by 0.29% to 10,529,358 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    5/20/26 12:25:29 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $1,225,101 worth of shares (398,985 units at $3.07), increasing direct ownership by 4% to 10,251,929 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/17/26 7:40:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $RDNT
    $TOI
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Names Minh Merchant Chief Legal Officer

    CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors. Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant

    4/6/26 9:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    $RDNT
    $TOI
    Financials

    Live finance-specific insights

    View All

    RadNet Reports Record First Quarter Financial Results and Revises Upwards 2026 Imaging Center Financial Guidance Ranges for Revenue, Adjusted EBITDA and Free Cash Flow

    Total Company Revenue increased 22.1% to $575.6 million in the first quarter of 2026 from $471.4 million in the first quarter of 2025Revenue from the Digital Health reportable segment increased 51.5% to $29.1 million in the first quarter of 2026 from $19.2 million in the first quarter of 2025; Annual Recurring Revenue(4) (ARR) increased from $49.8 million at March 31, 2025 to $96.9 million at March 31, 2026Total Company Adjusted EBITDA(1) was $63.3 million in the first quarter of 2026 as compared with $46.4 million in the first quarter of 2025, an increase of 36.3%; Digital Health reportable segment Adjusted EBITDA(1) decreased to $1.3 million in the first quarter of 2026 from $3.7 million i

    5/10/26 4:05:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    The Oncology Institute Reports First Quarter 2026 Financial Results

    CERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2026. Recent Operational Highlights Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 78% in the quarter as compared to prior year same quarter, reflecting the volume growth across our membership and continued attachment rate improvements.Contract expansion bringing our total Medicare Advantage lives to 200,000 across 25 counties in Florida effective July 1, 2026.  Preparing to launch our propr

    5/7/26 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    RadNet, Inc. Announces Date of its First Quarter 2026 Financial Results Conference Call

    LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it will host a conference call to discuss its first quarter 2026 financial results on Monday, May 11, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-744-1280. International callers can dial 412-564-6465. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1761306&tp_key=ea5d61284c. An archived replay of the call will also be available

    4/28/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    $TOI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care